Korro Bio, Inc. Paid-in-Kind Interest
Korro Bio, Inc. (KRRO) reported Paid-in-Kind Interest of $396.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2023-03-10
- Korro Bio, Inc. paid-in-kind interest for the quarter ending 2022-12-31 was -$25.00K, a 114.88% decline year-over-year.
- Korro Bio, Inc. paid-in-kind interest for the quarter ending 2022-09-30 was -$22.00K, a 113.50% decline year-over-year.
- Korro Bio, Inc. paid-in-kind interest for the quarter ending 2022-06-30 was $177.00K, a 1006.25% increase year-over-year.
- Korro Bio, Inc. paid-in-kind interest for the quarter ending 2022-03-31 was $266.00K.
- Korro Bio, Inc. paid-in-kind interest for fiscal 2022 was $396.00K, a 14.12% increase from fiscal 2021.
- Korro Bio, Inc. paid-in-kind interest for fiscal 2021 was $347.00K.
- Korro Bio, Inc. paid-in-kind interest for fiscal 2018 was $106.00K, a 39.08% decline from fiscal 2017.
- Korro Bio, Inc. paid-in-kind interest for fiscal 2017 was $174.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$47.00K derived: sum of 2 quarters · filed 2023-03-10 | $130.00K derived: sum of 3 quarters · filed 2023-03-10 | $396.00K 10-K · filed 2023-03-10 |
| 2022-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $155.00K derived: sum of 2 quarters · filed 2022-11-08 | $421.00K 10-Q · filed 2022-11-08 | $589.00K derived: sum of 4 quarters · filed 2023-03-10 |
| 2022-06-30 | $177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $443.00K 10-Q · filed 2022-08-09 | $611.00K derived: sum of 3 quarters · filed 2023-03-10 | $774.00K derived: sum of 4 quarters · filed 2023-03-10 |
| 2022-03-31 | $266.00K 10-Q · filed 2022-05-04 | $434.00K derived: sum of 2 quarters · filed 2023-03-10 | $597.00K derived: sum of 3 quarters · filed 2023-03-10 | $613.00K derived: sum of 4 quarters · filed 2023-03-10 |
| 2021-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $331.00K derived: sum of 2 quarters · filed 2023-03-10 | $347.00K derived: sum of 3 quarters · filed 2023-03-10 | $347.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $179.00K derived: sum of 2 quarters · filed 2022-11-08 | $179.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $16.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-04 | |||
| 2018-12-31 | $106.00K 10-K · filed 2020-03-26 | |||
| 2017-12-31 | $174.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |